Form D · Biotechnology
Invea Therapeutics, Inc
Guilford, CT · CIK 0001906425
Offering snapshot reported Dec 10, 2025 · SEC filing
- Reported sold
- $120K Offering amount: $120K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Oct 31, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 10, 2025 | Initial | $120,250 | No comparison | 1 | SEC filing |
| Apr 9, 2025 | Initial | $300,000 | No comparison | 2 | SEC filing |
| Apr 22, 2022 | Initial | $1,524,994 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-566314
Source: Form D, filed Dec 10, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael J. Aiello | Executive |
| Salvatore Alesci | Executive |
| Kerrie Brady | Director |
| Stephen Doberstein | Director |
| Aman Kant | Executive |
| Demetrios Kydonieus | Director |
| Sandeep Laumas | Director |
| Vimal Mehta | Director |
| Krishnan Nandabalan | Director, Executive |
| Shunichiro "Steve" Okada | Executive |
| Jonathan Zalevsky | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2614 Boston Post Road, Suite 33 B
Guilford, CT, 06437
Guilford, CT, 06437